期刊文献+

急性心力衰竭药物治疗临床研究新进展 被引量:6

New progress on the drug therapy of acute heart failure
原文传递
导出
摘要 急性心力衰竭(AHF)是心脏慢性疾病的急性发作,其发病率、死亡率均较高,严重影响患者的生活质量,增加经济负担。本文主要综述AHF治疗药物研究进展以及射血分数降低心力衰竭(HFr EF)的药物治疗,以期为临床治疗提供新的依据。 Acute heart failure(AHF) is an acute attack of chronic heart disease, which has high morbidity and mortality, the quality of life is seriously affected and the economic burden of patients is increased. This review summarizes the research progress of AHF therapeutic drugs and treatment drugs for HFr EF, in order to provide a new basis for clinical
作者 郑刚 ZHENG Gang(Department of Cardiology, Tianjin Third Central Hospital Branch, Tianjin 300250, Chin)
出处 《世界临床药物》 CAS 2018年第4期276-279,共4页 World Clinical Drug
关键词 急性心力衰竭(AHF) 药物 临床治疗 acute heart failure (AHF) drug treatment
  • 相关文献

参考文献2

二级参考文献34

  • 1Riet EESV, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review E J]. Eur J Heart Fail, 2016, 18 (3) : 242-252.
  • 2von Lueder TG, Krum H. New medical therapies for heart failure[J]. Nat Rev Cardiol, 2015, 12 (12): 730-740.
  • 3Castrini AI, Carubelli V, Lazzarini V, et al. Serelaxin a novel treatment for acute heart failure [J]. Expert Rev Clin Pharmacol, 2015, 8 (5) : 549-557.
  • 4Kumar VA, Viau D, Levy P. New drugs you are going to read about: serelaxin, ularitide, TRV027 [J]. Curt Emerg Hosp Med Rep, 2015, 3 (2) : 66-73.
  • 5Sato N, Takahashi W, Hirayama A, et al. Multicenter, randomized, double-blinded, placebo-controlled phase II study of serelaxin in Japanese patients with acute heart failure [J]. Circ J, 2015, 79 (6) : 1237-1247.
  • 6Dahlke M, Ng D, Yamaguchi M, et al. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations [J]. J Clin Pharmacol, 2015, 55 (4) : 415-422.
  • 7Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF tria[J]. Eur Heart J, 2014, 35 (16) : 1041-1050.
  • 8Felker GM, Teerlink JR, Butler J, et al. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX- AHF study[J]. JAm Coil Cardiol, 2014, 64 (15) : 1591-1598.
  • 9Bramlage P, Swift SL, Thoenes M, et al. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease [J]. Eur J Heart Fail, 2016, 18(1): 28-37.
  • 10Liu LC, Schutte E, Gansevoort RT, et al. Finerenone: third- generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease[J]. Expert Opin Investig Drugs, 2015, 24 (8) : 1123-1135.

共引文献23

同被引文献72

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部